Clinical Rheumatology

, Volume 26, Issue 6, pp 1025–1026 | Cite as

Severe gastrointestinal involvement in systemic sclerosis

  • Sotiris C. PlastirasEmail author
  • Michael Tzivras
  • Panayiotis G. Vlachoyiannopoulos
Case Report


Gastrointestinal tract (GIT) is the most common organ system involved in systemic sclerosis (SSc). GIT involvement is mainly attributed to GIT dismobility and wide mouth diverticular. GIT involvement in SSc can be also severely debilitating and even life threatening. To our knowledge, the presence of gastrointestinal bleeding due to the presence of multiple peptic ulcers in scleroderma patients is not well described. In this case report, we describe a scleroderma patient with recurrent gastrointestinal bleeding due to multiple peptic ulcers, in which vagotomy, pyloroplasty, and cholocystectomy were performed and subcutaneous somatostatin was administered to discontinue the recurrent bleeding and stabilize her clinical condition.





All of the authors participated in the writing of the manuscript.


  1. 1.
    Jaovisidha Kanyakorn, Csuka ME, Almagro Urias, Soergel Konrad (2005) Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum 34:689–702 (Feb)PubMedCrossRefGoogle Scholar
  2. 2.
    Valle JD, Scheiman JM (1999) Zollinger–Ellison syndrome. In: Yamada T, Alpers DH, Laine L, Owyang C, Powell DW (eds) Textbook of Gastroenterology, 3rd edn. Williams & Wilkins, Philadelphia, pp 1445–1462Google Scholar
  3. 3.
    Frucht H, Howard JM, Slaff JI et al (1989) Secretin and calcium provocative tests in the Zollinger–Ellison syndrome. Ann Intern Med 111:713–722PubMedGoogle Scholar
  4. 4.
    McGuigan JE, Wolfe MM (1980) Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 81:758–762Google Scholar
  5. 5.
    Mignon M, Rigaud D, Cambray S et al (1985) A comparative evaluation of secretin bolus and secretin infusion as secretin provocation tests in the Zollinger–Ellison syndrome. Scand J Gastroenterol 20:791–797PubMedGoogle Scholar
  6. 6.
    Matsui T, Iida M, Nanbu T et al (1985) A study of secretin dosage of secretin provocation test in the Zollinger–Ellison syndrome. Nippon Shokakibyo Gakkai Zasshi [Jpn J Gastroenterol] 82:288–295Google Scholar
  7. 7.
    Yamamoto C, Aoyagi K, Iwata K, Morita I, Hotokezaka M, Funakoshi S, Sakamoto K, Iida M, Sakisaka S (2005) Double doses of secretin contribute to diagnosis of Zollinger–Ellison syndrome in secretin and selective arterial secretion injection tests—a case report. Dig Dis Sci 50:2034–2036 (Nov)PubMedCrossRefGoogle Scholar
  8. 8.
    Medsger TA Jr (2001) Systemic sclerosis (Scleroderma): clinical aspects. In: Koopman WJ (ed) Arthritis and allied conditions. Williams & Wilkins, Philadelphia, PA, pp 1590–1624Google Scholar
  9. 9.
    Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2006

Authors and Affiliations

  • Sotiris C. Plastiras
    • 1
    • 2
    Email author
  • Michael Tzivras
    • 1
    • 2
  • Panayiotis G. Vlachoyiannopoulos
    • 1
    • 2
  1. 1.Department of PathophysiologyUniversity of Athens Medical SchoolAthensGreece
  2. 2.Laiko University HospitalAthensGreece

Personalised recommendations